Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes

Phase 1

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Insulin Lispro SAR342434

First Posted Date: 2019-04-04

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 90

Registration Number: NCT03903016

Locations: 🇩🇪
Investigational Site Number 2760001, Neuss, Germany

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: SAR442168
Drug: Placebo
Drug: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)

First Posted Date: 2019-03-26

Last Posted Date: 2023-03-08

Lead Sponsor: Sanofi

Target Recruit Count: 130

Registration Number: NCT03889639

Locations: 🇺🇸
Investigational Site Number 8400005, Cullman, Alabama, United States
🇺🇸
Investigational Site Number 8400002, Maitland, Florida, United States
🇺🇸
Investigational Site Number 8400004, Sunrise, Florida, United States

and more 45 locations

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin Aspart SAR341402
Drug: Insulin Aspart
Drug: Insulin glargine U100

First Posted Date: 2019-03-14

Last Posted Date: 2024-04-17

Lead Sponsor: Sanofi

Target Recruit Count: 210

Registration Number: NCT03874715

Locations: 🇺🇸
Investigational Site Number 8400014, Concord, California, United States
🇺🇸
Investigational Site Number 8400038, Doral, Florida, United States
🇺🇸
Investigational Site Number 8400027, Houston, Texas, United States

and more 30 locations

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Neoplasm

Interventions: Drug: SAR441000
Drug: Cemiplimab REGN2810

First Posted Date: 2019-03-12

Last Posted Date: 2024-03-05

Lead Sponsor: Sanofi

Target Recruit Count: 77

Registration Number: NCT03871348

Locations: 🇺🇸
Dana Farber Cancer Institute Site Number : 8400003, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Foundation Site Number : 8400007, Cleveland, Ohio, United States
🇺🇸
~University of Texas - MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States

and more 17 locations

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Isatuximab
Drug: Dexamethasone or equivalent
Drug: Fludarabine
Drug: Cytarabine
Drug: Liposomal daunorubicin
Drug: Daunorubicin (nonliposomal)
Drug: Idarubicin
Drug: Filgrastim or equivalent
Drug: Mitoxantrone
Drug: Doxorubicin
Drug: Vincristine
Drug: Pegaspargase (PEG) Asparaginase
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Methotrexate
Drug: L - Asparginase
Drug: Hydroxyurea
Drug: L - Asparaginase (Erwinase)

First Posted Date: 2019-03-04

Last Posted Date: 2024-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 67

Registration Number: NCT03860844

Locations: 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽
Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷
Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: TERIFLUNOMIDE HMR1726

First Posted Date: 2019-02-27

Last Posted Date: 2023-04-19

Lead Sponsor: Sanofi

Target Recruit Count: 121

Registration Number: NCT03856619

Locations: 🇮🇳
Investigational Site Number :026, Gurgaon, India
🇮🇳
Investigational Site Number :014, Pune, India
🇮🇳
Investigational Site Number :007, Gurgaon, India

and more 11 locations

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Active, not recruiting

Conditions: Dermatitis Atopic

Interventions: Other: Blood sample
Other: Cheek swab

First Posted Date: 2019-02-21

Last Posted Date: 2024-05-02

Lead Sponsor: Sanofi

Target Recruit Count: 266

Registration Number: NCT03849716

Locations: 🇫🇷
Investigational Site Number : 2500003, Paris Cedex 15, France
🇲🇽
Investigational Site Number : 4840006, Mexico, Mexico
🇳🇱
Investigational Site Number : 5280005, Groningen, Netherlands

and more 45 locations

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Amcenestrant (SAR439859)

First Posted Date: 2019-01-25

Last Posted Date: 2025-05-14

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT03816839

Locations: 🇯🇵
Investigational Site Number : 3920003, Nagoya-shi, Aichi, Japan
🇯🇵
Investigational Site Number : 3920002, Chuo-ku, Tokyo, Japan
🇯🇵
Investigational Site Number : 3920001, Kashiwa-shi, Chiba, Japan

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Healthy Subjects

Interventions: Drug: Sotagliflozin (SAR439954)
Drug: 14C-microtracer
Drug: Charcoal

First Posted Date: 2019-01-14

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT03802487

Locations: 🇬🇧
Investigational site number 8260001, Nottingham, United Kingdom

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Drug: Insulin glargine (HOE901)
Drug: Metformin

First Posted Date: 2019-01-09

Last Posted Date: 2022-07-19

Lead Sponsor: Sanofi

Target Recruit Count: 426

Registration Number: NCT03798080

Locations: 🇨🇳
Investigational Site Number 1560054, Changchun, China
🇨🇳
Investigational Site Number 1560005, Changchun, China
🇨🇳
Investigational Site Number 1560025, Fuzhou, China

and more 42 locations

Home Terms & Conditions Privacy Policy